Genfit S.A. (GNFT)
3.87
-0.05 (-1.28%)
At close: Feb 21, 2025, 11:54 AM
undefined% (undefined)
| Bid | 3.87 |
| Market Cap | 192.98M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.39 |
| PE Ratio (ttm) | 9.92 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.05 |
| Volume | 8,741 |
| Avg. Volume (20D) | 8,757 |
| Open | 3.88 |
| Previous Close | 3.92 |
| Day's Range | 3.87 - 3.90 |
| 52-Week Range | 3.35 - 6.42 |
| Beta | undefined |
About GNFT
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 27, 2019
Employees 169
Stock Exchange NASDAQ
Ticker Symbol GNFT
Website https://www.genfit.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GNFT stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 235.92% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
5 months ago
+15.51%
GENFIT shares are trading higher. The company repo...
Unlock content with
Pro Subscription
